학술논문

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.
Document Type
Article
Source
Nature Communications; 2/6/2024, Vol. 15 Issue 1, p1-15, 15p
Subject
ADULT respiratory distress syndrome
CYTOTOXIC T cells
KILLER cells
T cells
T cell receptors
CELLULAR therapy
CLINICAL trials
EXTRACORPOREAL membrane oxygenation
Language
ISSN
20411723
Abstract
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)